The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice.
Henry S. Friedman
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Roche/Genentech
James Emmett Herndon
No relevant relationships to disclose
Frances McSherry
No relevant relationships to disclose
Arliene Ravelo
Employment or Leadership Position - Genentech
Stock Ownership - Roche Holdings
Eric S Lipp
No relevant relationships to disclose
Patrick Healy
No relevant relationships to disclose
Katherine B. Peters
No relevant relationships to disclose
Tulika Ranjan
No relevant relationships to disclose
Gordana Vlahovic
Honoraria - Genentech
Jason Watts
No relevant relationships to disclose
John Howard Sampson
No relevant relationships to disclose
Allan H. Friedman
No relevant relationships to disclose
Annick Desjardins
Consultant or Advisory Role - Roche/Genentech
Research Funding - Roche/Genentech